The U.S. Federal Trade Commission, joined by Utah and California officials, sued Hims & Hers alleging the telehealth provider shared sensitive health information with third-party advertising platforms while marketing its privacy practices as protective. The complaint also challenges billing and cancellation conduct tied to intake submissions. FTC investigators alleged Hims charges consumers for prescriptions almost immediately after intake form submission, despite telling users they will consult with a medical provider. The complaint further says consumers struggle to cancel subscriptions and that health data were shared with Meta, Snap and other parties. The case underscores ongoing enforcement pressure on DTC health platforms that monetize audiences via tracking and targeted advertising, even when the customer-facing language emphasizes privacy and medical consultation. For biotech-adjacent companies operating patient-facing digital health or telehealth programs, the decision risk concentrates around consent clarity, data handling disclosures, and billing transparency.